A comparative study of two PODXL antibodies in 840 colorectal cancer patients

BACKGROUND: Podocalyxin (PODXL) is a transmembrane sialomucin, whose aberrant expression and/or allelic variation associates with poor prognosis and unfavourable clinicopathological characteristics in different cancers. Membranous expression of PODXL has been suggested to be an independent marker of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kaprio, Tuomas, Hagström, Jaana, Fermér, Christian, Mustonen, Harri, Böckelman, Camilla, Nilsson, Olle, Haglund, Caj
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4107962/
https://ncbi.nlm.nih.gov/pubmed/25004935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-494
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars